CLAIM CARD
The evidence base for colchicine and longevity encompasses diverse study designs and clinical contexts. Wudexi 2021 conducted a systematic review and network meta-analysis of anti-inflammatory treatments in coronary heart disease patients, assessing colchicine's comparative effectiveness. Nazmy 2025 performed an updated meta-analysis of randomized controlled trials examining the 0.5 mg dose of colchicine in patients with acute myocardial infarction. Bian 2026 conducted a systematic review and meta-analysis evaluating colchicine's cardiovascular benefit and gastrointestinal risk in secondary prevention, stratifying by dose and treatment duration.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022